AlphAIAlphAI — Financial news for AI agents
tradingview.com

BTIG maintains Carlsmed at Buy, raises price target to $26 from $24

BTIG reaffirmed its Buy rating for Carlsmed and increased its price target to $26 from $24, representing an 8.3% rise. This target suggests a 76.8% upside from the Nov 10 closing price of $14.71.

Original reporting
tradingview.com
Published Nov 11, 2026, 9:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 9:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG maintains Carlsmed at Buy, raises price target to $26 from $24 — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade suggests upside potential but lacks detailed justification.

02

Market read

Analyst rating change provides a modest trading cue for Carlsmed shareholders.

03

What to watch

Analyst's rationale and valuation assumptions are not disclosed.

Relevance 6/10Novelty 5/10Timing: today

Background

BTIG issued a new Buy rating and raised Carlsmed's price target from $24 to $26.

Market effects

Sector

Limited impact; analyst upgrade may slightly lift biotech sentiment.

Regional

Minor effect on Nordic biotech listings.

Global

Low; confined to Carlsmed investors.

Counterpoint

What could challenge this read

Price target raise may be premature if upcoming trial data disappoints.

Key entities

  • company
    Carlsmed

    Swedish biotech firm subject of the analyst rating.

  • analyst_firm
    BTIG

    Research house that issued the rating.

Read at source← All news

Related articles

$CARLHigh

Carlsmed (CARL) Q3 2026 Earnings Call Transcript

Carlsmed (CARL) reported 65% revenue growth in Q3 2026, raising full-year guidance to $78M-$80M. The company launched new products and expects 2027 catalysts. Management updates include new COO, CFO, and Chief Product & AI Officer. Clinical data shows reduced reoperation rates, and new reimbursement codes may boost hospital adoption.

finance.yahoo.com
$CARLMed

Carlsmed Q3 Earnings Call Highlights

Carlsmed (NASDAQ:CARL) plans to enroll patients in a registry for its aprevo Cervical product in Q4. The company expects a change in reimbursement coding to boost lumbar procedure growth. Carlsmed launched its aprevo posterior bilateral procedure in mid-October and plans to launch its corra cervical plating system soon. Q3 gross margin improved to 77.3%, but adjusted EBITDA remained negative at -$7.3M. The company ended Q3 with $80.3M in cash and investments.

finance.yahoo.com
$CARLHigh

Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance

CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, CALIFORNIA, NOVEMBER 10, 2026 (

SEC EDGAR 8-K